PerkinElmer Grants GenMark License to Microfluidics Patent Portfolio | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GenMark Diagnostics today said it has been granted a non-exclusive license to PerkinElmer's microfluidics patent portfolio.

Financial and other terms of the deal were not disclosed.

GenMark President and CEO Hany Massarany said in a statement, "Completing this agreement strengthens GenMark's patent portfolio and provides us with maximum flexibility as we expand our menu of high-value multiplex molecular tests."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.